Genentech
A Member of the Roche Group

2019 Independent Medical Education Call for Grant Notification

Issue Date: **January 13, 2020**

The *Independent Medical Education team at Genentech, a member of the Roche Group,* invites accredited educational providers to submit applications for independent, certified medical education grants subject to the terms described below. This Call for Grants Notification (CGN) provides public notice of the availability of funds in a general topic area for activities for which recognized scientific or educational needs exist and funding is available.

Purpose: As part of Genentech's scientific mission, Genentech supports grants for independent medical education that aim to improve patient care by focusing on the improved application of knowledge, competence, and performance among healthcare professionals. This mission is achieved by supporting quality independent education that addresses evidence-based, bona fide educational gaps in accordance with the ACCME, AMA, PhRMA Code, OIG and FDA guidance.

Notification: Genentech CGNs are made available through our online Genentech Funding Request System (gFRS) site (http://funding.gene.com) along with the websites for the Alliance for Continuing Education in the Health Professions (ACEhp) and the Society for Academic Continuing Medical Education (SACME). In addition, an email is distributed to all registered gFRS users who have previously applied for support of an independent education activity. *There have been no predetermined approvals, nor any identified preferred educational providers. All submissions will be reviewed equally and thoroughly.*

Terms and Conditions

1. All grant applications received in response to this CGN will be reviewed in accordance with all Genentech policies and policy guidelines. (Please refer to the publicly available criteria on http://funding.gene.com)
2. This CGN does not commit Genentech to award a grant or pay any costs incurred in the preparation of a response to this request.
3. Genentech reserves the right to approve or deny any or all applications received as a result of this request or to cancel, in part or in its entirety, this CGN.
4. For compliance reasons, and in fairness to all providers, all communications about this CGN must come exclusively to Genentech's department of Medical Education and Research Grants. Failure to comply will automatically disqualify providers.
5. Failure to follow the instructions within this CGN may result in a denial.

Instructions

Eligibility Criteria	• U.S. based education provider • Registered account in gFRS • Accredited to provide CME/CE and in good standing (e.g. ACCME, ANCC, ACPE, etc.)
Geographical Scope	• Educational initiatives must be U.S.-based only

Genentech
A Member of the Roche Group

Submission Directions	Application Process	Deadlines
Step 1	Providers who meet the eligibility criteria and are interested in submitting a response to this CGN will have 3 weeks to complete a brief ***Executive Summary*** through the Genentech CGN Executive Summary link. https://forms.gle/Z5Co4M97siV8vnqr5	February 3, 2020
Step 2	After 2 weeks, respective Genentech Medical Education Managers will notify (via email) those providers whose Executive Summaries were selected for further review.	February 17, 2020
Step 3	Those providers who receive notification of potential interest will have 3 weeks to **submit full grant application(s)** online through gFRS. Further instructions will be provided in the email notification.	March 9, 2020
Step 4	Notification of final decisions will occur via email	March 23, 2020
Step 5	Funded Project Start Date: within 12 weeks of grant award and interim update by 4-6 weeks	June 19, 2020

Additional Considerations

Provider(s) who are awarded grants are encouraged but not required to:

1. Demonstrate key findings via outcomes analysis and report the extent to which the education met the stated objectives and other key findings.
2. Describe how learners demonstrated competence, performance, or patient outcomes improvement as a result of the educational activity.
3. Summarize (through written analysis) the provider's understanding and interpretation of the outcomes data and identify any persistent educational gaps, unanticipated barriers and/or activity/outcomes limitations.

Genentech
A Member of the Roche Group

Currently Available CGN Focus Area(s):

Focus	Opportunity
Therapeutic Area: Respiratory **Disease:** Nasal Polyp **Learning Audience:** Otolaryngology **Support Available:** Up to $375,000 Knowledge- and Competence-based Emerging Education *(Understanding & Addressing national or local gaps)*	• Nasal polyps are a common and potentially debilitating condition in adults, impacting 13 million people in the U.S.[1,2] Currently, there are limited treatment options available and many patients opt for nasal surgery or systemic steroids, which often cannot effectively control symptoms over time due to nasal polyp regrowth. • Frequently co-occurring with other respiratory conditions, nasal polyps impacts approximately 45 percent of people with adult-onset asthma and approximately 30 percent of people with chronic rhinosinusitis, resulting in chronic rhinosinusitis with nasal polyps (CRSwNP) if the nasal polyps and sinusitis symptoms are present for 12 weeks or longer[3,4]. • After sinus surgery, nasal polyps recur in up to 80 percent of people, with approximately 40 percent requiring at least one further surgery[5]. • Genentech is seeking to support multiple independent medical education activities (CME/CE) designed to enhance the understanding of potential treatment options available and disease education. **References** 1. U.S. Census Bureau Population Estimates (2018). QuickFacts. Available at: https://www.census.gov/quickfacts/fact/table/US/PST045218. 2. Stevens, W. W., Schleimer, R. P., & Kern, R. C. (2016). Chronic Rhinosinusitis with Nasal Polyps. *The Journal of Allergy and Clinical Immunology*. In practice, 4(4), 565–572. 3. Mayo Clinic. Nasal Polyps. Available at: https://www.mayoclinic.org/diseases-conditions/nasal-polyps/symptoms-causes/syc-20351888. Accessed October 2019. 4. Bachert, Claus et al. (2015) Current and future treatment options for adult chronic rhinosinusitis: Focus on nasal polyposis, Journal of Allergy and Clinical Immunology, 136 (6), 1431 – 1440. Available at: https://www.jacionline.org/article/S0091-6749(15)01511-0/fulltext. 5. American Academy of Allergy, Asthma & Immunology (2017, October 17). *Development from Nasal Polyps to Asthma: Different Disease Courses*. Available at:: https://www.aaaai.org/global/latest-research-summaries/New-Research-from-JACI-In-Practice/nasal-polyp-asthma. 6. J Allergy Clin Immunol. 2018 May;141(5):1726-1734. doi: 10.1016/j.jaci.2018.01.031.

Genentech
A Member of the Roche Group